INTRODUCTION {#sec1}
============

Biobanks[^1^](#fn1){ref-type="fn"} have emerged as a significant research tool, gaining support from both the scientific community and regional, national and international research funding agencies. However, developing and maintaining these platforms is expensive. Indeed, in a recent survey of operational personnel representing 456 biobanks, funding shortages concerned 71% of those surveyed and 37% identified 'funding' as 'the biobank\'s greatest challenge.'[^2^](#fn2){ref-type="fn"} Thus, unsurprisingly, biobanks may seek support from the private sector or philanthropic organizations, which have an interest in sustaining them as research resources.

The scientific community is also increasingly facing pressure to commercialize and translate their work, thus increasing expectations of industry partnerships.[^3^](#fn3){ref-type="fn"} Funding agencies, in part, create and reinforce this commercialization pressure, by earmarking grants for projects that aim to bring products and therapies to the market within a short amount of time.[^4^](#fn4){ref-type="fn"} This commercialization process creates a range of policy challenges for scientists, research participants, and funders.

The goal of this document is to outline the policy issues associated with the commercialization of biobanks and, where possible, to review the relevant evidence and/or ethical and legal norms.[^5^](#fn5){ref-type="fn"} We do not attempt to provide suggestions for policy reform. Nevertheless, given that securing funding for biobanks remains a challenge and that researchers are increasingly pressured to work with industry and to rapidly translate their work, a scoping document of this nature---one that draws together international expertise and relevant research---seems timely and, we hope, can stand as a resource for future research and policy work.

'Commercialization' can refer to a number of different activities. It can refer to the commercialization of biobank resources (data or samples of human biological material) or of research results derived or products developed from those resources. It can also refer to publicly funded biobanks partnering with or receiving funding from private, for-profit entities like biotech companies, pharmaceutical corporations, or the medical device industry. For the purposes of this scoping document, we will largely focus on the introduction of private funding and partnerships to an existing, publicly funded biobank. This focus is justified because many biobanks are not-for-profit entities associated with larger (often publicly-funded) bodies, such as universities and hospitals, and funded, often through short-term grants, by these bodies, by the government, or by a mixture of public and private funds.[^6^](#fn6){ref-type="fn"} Survey evidence indicates that these biobanks are greatly concerned with securing adequate long-term funding.[^7^](#fn7){ref-type="fn"} As Meijer and colleagues note, with the expansion and change in the size, goals and structure of biobanks, 'stable sources of core funding will be necessary in most cases, from the public sector, patient organizations and private foundations.'[^8^](#fn8){ref-type="fn"} Given this reality, we believe that commercialization will particularly and uniquely impact publicly supported biobanks, as they consider various means, including private partnerships, to ensure financial security.[^9^](#fn9){ref-type="fn"}

Of course, biobanks vary greatly in organization, priorities, and funding,[^10^](#fn10){ref-type="fn"} and thus commercialization will affect different biobanks in different ways. Not every biobank will seek commercial partnerships in response to financial pressures, and, indeed, delineating which factors (eg type of biobank; organizational structure; research goals and focus) influence the development of private partnerships may be an important question for future research. Indeed, we hope this overview of issues will inform these future funding decisions.

In addition to our primary focus on the introduction of private financing and partnerships, some of the emerging research and commentaries on the issues associated with commercialization are relevant to a range of other activities and are worth considering here. For example, issues of public trust can be triggered by a variety of commercialization practices, as we will see. Thus, where appropriate, we will discuss commercialization activities beyond just the introduction of private funding.

Before turning to the issues at hand, it may be useful to set out some of the scenarios in which commercialization may occur. In this paper, as noted, we largely concentrate on the introduction of private funding to a pre-existing publicly funded biobank. In such a case, a chief concern for the biobank will be retaining participants who were, presumably, originally recruited with an understanding that the biobank would be a 'public good.' In this case, issues related to consent, participant retention, and withdrawal of biological material and associated data are particularly important. We can contrast this with a scenario in which the biobank is a public-private partnership from its inception. In such as case, enrollment of participants and obtaining consent to commercial imperatives, if any, are likely to be the prime focuses of the biobank. The different situations of these biobanks may inform and nuance the discussion that follows.

ISSUES {#sec1-1}
------

### Public Trust and Public Expectations {#sec1-1-1}

Trust is critical in determining whether people will participate in and support biobanking research. Public trust and how it influences the public\'s support for science is complex and influenced by many factors, including perceptions of the actors and institutions involved in research.[^11^](#fn11){ref-type="fn"} There is little doubt that the general public places a good deal of trust in the university-based scientific community. For example, a 2013 survey of United Kingdom residents commissioned by the Wellcome Trust found that 66% percent of respondents completely trusted or had a great deal of trust in university scientists.[^12^](#fn12){ref-type="fn"} However, it also showed that trust evaporated quickly if scientists worked for either industry (trusted by 32% of respondents) or government (trusted by 34% of respondents).[^13^](#fn13){ref-type="fn"} This has also been the case in Australia, where the Swinburne National Technology and Society Monitor has consistently found high public trust in scientists, universities and government research organizations.[^14^](#fn14){ref-type="fn"} Trust in public research institutions remains high even for controversial medical research (including some research in genetics), but decreases significantly with industry involvement.[^15^](#fn15){ref-type="fn"}

The involvement of industry in research seems to have considerable influence on public trust in science, irrespective of the type of research.[^16^](#fn16){ref-type="fn"} This holds true in the biobanking context, as well. Several studies show that many participants have a negative attitude towards the involvement of commercial entities in biobanks and biobanking research.[^17^](#fn17){ref-type="fn"} A survey of 1,201 Albertans found that public trust in biobanking research decreases substantially if industry is involved: 45.1% of those surveyed indicated they had 'a great deal' of trust in university-funded scientists; 19.5% had 'a great deal' of trust in university scientists funded by industry; and only 6% had similar trust in biobanking research conducted by for-profit industry.[^18^](#fn18){ref-type="fn"} A recent public opinion study of cancer patients similarly showed that 40.4% of participants reported having 'a great deal' of trust in biobanking research performed by government-funded university researchers as opposed to 16.3% and 3.2% of respondents reporting 'a great deal' of trust in industry-funded university research and research conducted by industry, respectively.[^19^](#fn19){ref-type="fn"} Interestingly, a study by Critchley and Nicol suggests that the type of organization (eg private entity versus university) has a greater impact on public trust than funding source (eg private versus public funding), though the source of funding also influences public trust.[^20^](#fn20){ref-type="fn"} Though their study was not specific to biobanking research, it may suggest that public biobanks which receive private funding will be better able to maintain public trust than those that are completely privately owned.

Many factors may account for a negative view of private investment in public biobanks. For instance, there is some evidence that members of the public fear that their donated biological samples and associated health data will be used in ways they find morally problematic, such as in research that may be stigmatizing or discriminatory to them and/or their communities[^21^](#fn21){ref-type="fn"} (for example, research connecting mental health with racial or ethnic background). Some biobank participants fear losing control over how their samples and data are used and with whom they are shared, and this fear may be heightened when for-profit companies invest in publicly funded biobanks. This notion is manifested in recent research by Critchley, Nicol, Otlowski and Chalmers (unpublished manuscript), which found that concern about sharing of genetic data with private entities was the chief reason for the significant erosion of support when genetic tests were conducted by a private company compared to those controlled by the public health care system.[^22^](#fn22){ref-type="fn"}

The public generally supports biobanking research,[^23^](#fn23){ref-type="fn"} though the terms on which people will participate and the expectations they have regarding participation are not uniform and differ on key matters like benefit sharing.[^24^](#fn24){ref-type="fn"} Some people participate for altruistic reasons, without expecting any benefits in return.[^25^](#fn25){ref-type="fn"} Other people are more likely to participate in biobanking research if they believe that biobanks will produce beneficial results for future patients and society.[^26^](#fn26){ref-type="fn"} Some participants do expect to receive something in return, including monetary reward, reduced costs of the (potential) clinical benefits derived from biobanking research, or the return of research results.[^27^](#fn27){ref-type="fn"} These observations also seem connected with the idea that private interests, including the introduction of industry funding, may limit sharing of biological material and associated data, prevent results from being returned, or limit public access to health benefits derived from private or proprietary research. The belief that public access to benefits will be reduced has been found to be an important reason for the decrease in public support for industry-based medical research (relative to publicly funded researchers).[^28^](#fn28){ref-type="fn"} This finding, combined with the public\'s desire for biobanks to share results and advance health care, suggests that some sort of benefit sharing arrangement or return of benefits back to the community may help the public accept the commercialization imperative.[^29^](#fn29){ref-type="fn"} Involvement of commercial entities, in the form of financial support for public biobanks, thus has the potential to change the motivations and expectations of the general public, hence altering the relationship between participants and biobanks. Of course, the particular way in which financial support from industry will affect this relationship and related motivations and expectations depends on many factors and may differ between distinct groups within the public.

The hype from genomics generally redounds to biobanks and this too might impact public expectations, such as the belief that biobanks will result in benefits in the near future.[^30^](#fn30){ref-type="fn"} If the benefits of biobanking are seen to be oversold, the involvement of commercial entities in the form of financial support is likely to garner even greater suspicion.[^31^](#fn31){ref-type="fn"} The expectation that public investment should yield results for the public good can be used to justify the creation of publicly funded biobanks and also the adoption of a range of biobanking policies that may be ethically or legally contentious (eg the use of a general or broad consent approach).[^32^](#fn32){ref-type="fn"} The involvement of industry can create questions about the degree to which the biobank research is being done solely---or even primarily---for the public good, thus compromising, in the eyes of the public, the validity of the justification for the adoption of these policies.

It seems reasonable to think that if the public perceives scientists from private research organizations to be more self-interested (ie for profit) than interested in the public good, this could diminish trust in biobanks that previously involved only publicly funded scientists, and thus hinder public participation. Yet this simple calculus has several limits. First, a sweeping statement that all public institutions are more trustworthy and private ones have motives contrary to the public good is a glaring oversimplification. Although we have referred to research which suggests that government-funded scientists are perceived to be more trustworthy than those working in private industry, there is an underlying distrust of the government as an overseer of biobanking practices.[^33^](#fn33){ref-type="fn"}

Second, trust in actors and institutions differs between various groups and may be influenced by factors such as race, gender, education, political or other ideology, religion, geography, and whether the individuals in question are impacted by a disease.[^34^](#fn34){ref-type="fn"} However, some evidence suggests that demographic factors have little impact on biobanking preferences and should not be viewed as determinative of peoples' biobanking preferences.[^35^](#fn35){ref-type="fn"}

Third, not everyone will reject participating in a biobank that has some commercial elements. Studies suggest that patient groups tend to be more accepting of pharmaceutical involvement than other civic groups, for example, and participants may be more at ease with commercialization elements if it means the biobank is 'governed or regulated' appropriately.[^36^](#fn36){ref-type="fn"} Additionally, not all 'private' actors are seen identically and not all 'public' sources are deemed trustworthy. The actual governance and operations of the biobank, whether it is partly or fully privately (ie pharmaceutical, philanthro-capital) or publicly (ie government, non-governmental, or government-legal) funded, and the nature and goals of the biobank likely influence individual perceptions of trust.[^37^](#fn37){ref-type="fn"}

Although considerable efforts have been made to understand the attitudes of the general public, patients, and other groups, and assess their willingness to participate in biobanking initiatives, more research is needed especially as it relates to the involvement of commercial entities in biobanking, in the form of financial support or access by privately-funded scientists to biobank resources.[^38^](#fn38){ref-type="fn"} Future research could focus on determining the perceived aspects of commercial involvement in biobanking that affect public trust (eg losing control over samples, misuse of biological samples and data, limited access to the benefits of research, the return of results, increased secrecy and limited sharing, and research misconduct and undertaking unethical research).[^39^](#fn39){ref-type="fn"} Participants may lack knowledge about biobanking and commercialization and desire to receive further information. If public communication and engagement are provided, will this lead to greater acceptance of commercial involvement in publicly-funded biobanks? And if so, under which conditions will the general public accept various types of commercial involvement in publicly funded biobanks? Further research could also explore whether and how the introduction of private funding or partnerships impacts the weighing of values and preferences that factor into an individual\'s decision about whether to participate in biobanking research.[^40^](#fn40){ref-type="fn"} By identifying how public trust is affected by different commercialization practices, future scholarship can simultaneously focus on the related issue of how to build or increase trust in public biobanks that partner with private entities. It may be, for example, that certain approaches to public-private partnerships---such as arrangements for benefit sharing---or actions by private entities---such as providing transparent information about intentions and goals and implementing open communication policies---will minimize the erosion of public trust that may accompany commercialization.

The current lack of consensus on many key biobanking issues[^41^](#fn41){ref-type="fn"} combined with strong public reactions to recent controversies relevant to biobanking, albeit in a different context (eg *Havasupai Tribe versus Arizona Board of Regents*; destruction of 5 million blood samples by Texas Department of State Health Services), should remind us that trust can easily sway and may have a profound impact on biobanking endeavors.[^42^](#fn42){ref-type="fn"}

### Conflicts of Interest {#sec1-1-2}

Commercialization may result in tension between the interests of private partners and those of the researchers or organizers of the biobank, which raises a number of interrelated concerns. If commercial entities contribute funding for biobanking research, scientists 'may relinquish part of their independence over the development of the research.'[^43^](#fn43){ref-type="fn"} Or procuring private investment or promoting the interests of commercial partners may trump other interests or priorities.[^44^](#fn44){ref-type="fn"} For example, a biobank might authorize secondary uses of data or samples that either risk misuse of the resource or are inconsistent with the consent of participants in order to secure private funding. Likewise, scientists may replace basic, essential research with commercially-profitable research.[^45^](#fn45){ref-type="fn"} Similarly, commercialization in the form of financial relationships between private entities and university scientists could compromise research integrity.[^46^](#fn46){ref-type="fn"} For example, studies in other fields of biomedical research have shown that 'industry-sponsored research tends to draw pro-industry conclusions.'[^47^](#fn47){ref-type="fn"} Public perception of biomedical science as a tool for the 'public good' may be negatively impacted by these outcomes.[^48^](#fn48){ref-type="fn"} As Hoeyer observes, 'commercial incentives might work contrary to the ambition of using stored tissue to address public health problems, both by impeding some research collaborations and by modifying the research agenda and our shared understanding as to what constitutes an important health problem.'[^49^](#fn49){ref-type="fn"}

### Consent {#sec1-1-3}

The issue of consent has proven to be one of the most divisive topics in the context of biobanking research. High profile tissue banking and genomic research cases---albeit not involving publicly funded population biobanks---and subsequent media attention surrounding these cases highlight the sensitivity of the consent issue and may contribute to increased scrutiny of biobanking practices.[^50^](#fn50){ref-type="fn"}

Consent issues typically arise in connection with the down-stream commercialization of products and therapies derived from research on biobank samples and data. Informed consent laws and norms require that researchers inform participants about potential commercial uses of their biological samples and data. But consent issues also emerge when considering the introduction of financial support by private entities to public biobanks, particularly if this possibility had not been addressed in the initial consent.

The importance of informing research participants about potential commercial applications resulting from research on their samples and data---an inevitable byproduct of industry involvement---has been endorsed by numerous guidelines and recommendations.[^51^](#fn51){ref-type="fn"} Disclosure is required, in part, because knowledge of potential commercial uses has been shown to be a relevant factor in the decision of individuals to participate in biomedical research. As noted above, studies[^52^](#fn52){ref-type="fn"} have reported that participants may see commercial applications at odds with their initial reasons for and expectations regarding participation.[^53^](#fn53){ref-type="fn"} It is an ethical imperative that scientists be transparent regarding intended commercial use and address participants' concerns related to commercialization.[^54^](#fn54){ref-type="fn"} Again, depending on the nature of the commercialization agreements, these kinds of concerns may be a natural consequence of industry funding of a public biobank.

Given the increasingly common use of 'broad consent'[^55^](#fn55){ref-type="fn"} by biobanks, there may be questions about the sufficiency of consent if commercialization plans and goals are not clarified at the outset. Many 'broad consents' forms in current use may refer, with legally sufficient specificity, to possible future commercial applications or industry involvement. However, if commercialization issues are not addressed, engaging a private entity post-original consent may necessitate a re-consent process.[^56^](#fn56){ref-type="fn"} In addition, an overly broad or generic reference to future commercialization activities may be insufficient. It has been argued, for example, that obtaining a broad consent to use samples for a wide range of commercial and non-commercial research in the future may be legally problematic and may require the provision of more detailed information about the nature of the commercial activity.[^57^](#fn57){ref-type="fn"}

Although informed consent is a mechanism for protecting participants' interests and promoting their autonomy, it has limitations.[^58^](#fn58){ref-type="fn"} Consent procedures need to be coupled with other governance mechanisms, such as ongoing monitoring by oversight committees, in order to ensure that biobank resources will be put to the best possible uses.[^59^](#fn59){ref-type="fn"} Prior consultation and communication with communities and interest groups should also be considered.[^60^](#fn60){ref-type="fn"} As Luther and Lemmens note, 'an over-emphasis on consent, without sufficient attention to societal, economic, structural and other challenges to individual decision-making, may undermine rather than protect the interest of individuals'.[^61^](#fn61){ref-type="fn"} As such, any consent mechanism or process that is put in place to address the involvement of private entities should be enhanced by appropriate, long-term oversight.

### Ownership, Access, and Control {#sec1-1-4}

The law relating to ownership and control of human biological material varies in different countries, and, in some countries, remains unclear.[^62^](#fn62){ref-type="fn"} In the United Kingdom, while courts have accepted that donors have some property rights in tissue set aside for future use, this right does not extend to tissue collected for research purposes.[^63^](#fn63){ref-type="fn"} In the United States, courts have consistently held that individuals do not retain ownership of material donated for research.[^64^](#fn64){ref-type="fn"} However, individuals may still exercise some degree of control over biological materials, as they are able to withdraw from research.[^65^](#fn65){ref-type="fn"} And the existing jurisprudence may be limited by the facts, making its application to other situations uncertain.[^66^](#fn66){ref-type="fn"} As a result, the law regarding ownership and control remains unclear.[^67^](#fn67){ref-type="fn"} In Canada, while courts have not decided the issue of ownership of human biological material used in research, individuals have a common law right to access and, likely, control their health information.[^68^](#fn68){ref-type="fn"} In Estonia, donated samples are owned by the institution overseeing the biobank.[^69^](#fn69){ref-type="fn"} In Portugal, the participant owns the donated samples.[^70^](#fn70){ref-type="fn"} Iceland does not use the term 'ownership' in its treatment of research samples.[^71^](#fn71){ref-type="fn"}

Additionally, survey research tells us that there is no consensus within the general public regarding who owns human biological material taken, stored and used for research. For instance, a survey of 1,201 Albertans revealed that 44.3% believed that the institution owned the samples, 25.7% felt that those who donated the samples owned them, 23.1% felt that the scientists owned the samples and 6.9% believed that the research funder owned the samples.[^72^](#fn72){ref-type="fn"}

As a result of this diversity of positions and legal uncertainty in several jurisdictions, many scholars have called for clarification on the proprietary rights (eg access, control) of donors, biobanks and researchers.[^73^](#fn73){ref-type="fn"} The involvement of private entities in a public biobank, and a concomitant need to understand who controls samples, seems likely to make clarification even more imperative.

### Sustainability and Bankruptcy {#sec1-1-5}

Biobanks are expensive to maintain.[^74^](#fn74){ref-type="fn"} A lack of sufficient funding may have a dramatic impact on sustainability and raise challenging policy issues. Two recent bankruptcies of private population biobanks, Genizon in Québec, Canada and deCODE Genetics in Iceland, illustrate the ethical and policy dimensions of the issues raised in this context. Both biobanks were privately owned and recruited their participants from homogeneous population groups originating in geographically determined locations.[^75^](#fn75){ref-type="fn"}

Given these similarities, it is interesting to note the different outcomes of bankruptcy in the two cases. deCODE (with 140,000 samples from the Icelandic population) first declared bankruptcy in 2009, selling its assets (including its biobank) to Saga Investments LCC. Saga is a group comprising some of the original investors in deCODE who kept running the company with a similar management structure. Following an unsuccessful attempt to pierce the direct-to-consumer (DTC) market, the company was acquired by the biotechnology giant Amgen for US\$415 million.[^76^](#fn76){ref-type="fn"} So far, the sale has not affected the management and objectives of the biobank, which remains located in Iceland.[^77^](#fn77){ref-type="fn"} As part of the deCODE licence, the government required that the biobank stay in Iceland, even if third parties became involved. However, Amgen has not offered any written guarantee that this arrangement will prevail over time and no court decision has been rendered to that effect. Genizon (with 50,000 samples from the French Québec founder population) was a Québec-based private biotechnology company in the business of mapping and identifying genes for complex disorders. It filed for bankruptcy and liquidated its tangible assets, excluding the biobank, in 2011.[^78^](#fn78){ref-type="fn"} Later that year, the Superior Court of Québec mandated Génome Québec (GQ), a provincial public funding agency, to act as the trustee of the biobank. In late 2012, Genome Québec launched a call for tenders with the hope of transferring Genizon\'s biobank to a Québec research centre.[^79^](#fn79){ref-type="fn"} Following the closure of the call for tenders, Genome Quebec turned down two valid bids by public groups deciding instead that it would continue managing the Genizon biobank by itself.[^80^](#fn80){ref-type="fn"}

In cases like this, what should happen to the samples and data of the participants? Can they be sold like other types of material assets? Transferred to another country? Or should they be destroyed instead? Responses to these questions could have far reaching implications for participants' privacy, autonomy and dignity. In the case of bankruptcy, the biobank\'s policies, especially those regarding data privacy and data sharing, are relevant for courts to determine the extent of what can be done with the participants' data and samples. The informed consent form signed by the participants will also play an important role in that respect, by creating conditions that should be respected post-bankruptcy. In this type of bankruptcy cases, US experts have alluded to the possibility of legally appointing a Consumer Privacy Ombudsman (CPO) to assist the court on privacy aspects of the process.[^81^](#fn81){ref-type="fn"} However, to require this special procedure, the proposed liquidation should meet strict criteria that likely would not apply to most cases involving genomic biobanks.[^82^](#fn82){ref-type="fn"} Given the sensitive nature of medical data, including genetic data and tissue samples, and the importance of preserving public trust in science, it appears that clear policies are required. Those policies should give weight to the promises made to research participants at the inception of a biobank and ensure more predictable outcomes in case of bankruptcy. However, developing such policies may be challenging, as issues relating to bankruptcy or biobank closure are rarely priorities at the inception of a biobank project[^83^](#fn83){ref-type="fn"} and tend to be considered only in times of hardship.

### Access Agreements {#sec1-1-6}

To protect the professional interests of scientists and the rights of research participants, biobanks are increasingly making use of a variety of access agreements. Usually some of the data from the biobank (eg summary reads, genotype frequencies, a limited amount of de-identified clinical data annotation fields) will be made available openly while the more sensitive data (eg gene expression data, raw genotypes, specific demographic data) and samples, if accessible at all, will be made available only to researchers who agree to comply with the terms of these access agreements.[^84^](#fn84){ref-type="fn"} This second mode of access is usually referred to as 'controlled access' or 'managed access' by the research community. A biobank access committee will usually have the responsibility of reviewing these access agreements and granting access to approved users. An intrinsic limitation of any current access agreement is the limited capacity of biobanks to effectively monitor compliance and sanction potential infringers.[^85^](#fn85){ref-type="fn"}

Access agreements offer important advantages to biobanks but can also generate substantial issues which the biobanks should strive to minimize. The current speed of progress in informatics and bioinformatics has made it increasingly possible to re-identify individuals from a small amount of genetic and/or clinical data and a matching database, limiting the effectiveness of traditional means of protecting the identity of research participants in open biobank projects (eg anonymization, coding, and de-identification).[^86^](#fn86){ref-type="fn"} Given this reality, it seems prudent to add another layer of protection that does not solely rely on technology.

However, it should be recognized that the imposition of an access agreement severely limits the open science nature of a biobank. Even the simplest access agreement containing a minimal number of restrictions may deter a substantial number of scientists from applying.[^87^](#fn87){ref-type="fn"} Similarly, agreements that restrict access to or dissemination of research data may undermine the free flow of scientific knowledge. An important related issue is the risk that some biobanks, in an attempt to meet their obligations to protect the rights of participants, will impose overly restrictive or unacceptable conditions on members of the scientific community. Clauses requiring users to sign collaboration agreements with biobanks, to agree to overly long moratorium periods before using the data, to return enriched data to the biobank, or to give a first right of refusal on potential emerging intellectual property are all examples of provisions that could severely limit the open science nature of a biobank. Requiring an unacceptably high amount of money as compensation for the provision of samples (under the pretense of cost recovery) would have a similar effect and could also be considered a commercial sale of the human samples, which is illegal in many jurisdictions.[^88^](#fn88){ref-type="fn"} This potential for misusing access agreements should be recognized[^89^](#fn89){ref-type="fn"} and biobank administrators should be careful to use these agreements in a way that will only minimally restrict open science for the real benefit of research participants. Therefore, the publication of consensus statements or harmonized models of acceptable clauses for access agreements might have a very positive impact on the current practices of biobanks.[^90^](#fn90){ref-type="fn"} However, in some cases, uniform policies may not address the unique circumstances of a particular biobank and thus context-specific clauses will be preferable.

CONCLUSION {#sec2}
==========

In addition to the issues examined above, introducing private funding into previously publicly-funded biobanks may exacerbate a range of other ethical issues.[^91^](#fn91){ref-type="fn"} For example, how to recognize the right to withdraw from research in the context of biobanking is a controversial matter.[^92^](#fn92){ref-type="fn"} The introduction of private entities or funding may further complicate the withdrawal issue because it may create obligations on scientists to share data with certain parties, including private partners, and data disseminated to them may be impossible to recall if a participant withdraws from the study.[^93^](#fn93){ref-type="fn"} Similarly, the involvement of private funders may exacerbate privacy issues or increase tensions related to privacy. While funding itself is likely not an issue *per se*, if biological material and data are shared with, for example, pharmaceutical companies, participants may feel as though their privacy has been violated, which, as discussed above, may negatively impact public trust in biobanks.[^94^](#fn94){ref-type="fn"} Finally, the proliferation of biobanks around the world and other technological innovations are increasingly making possible wide-spread sharing of data and biological samples, a practice which is encouraged in order to realize the economic and scientific potential of biobanks.[^95^](#fn95){ref-type="fn"} This practice may be impacted or hindered by the introduction of private funding and collaboration with private entities, as the expectations of private entities and agreements governing such partnerships may create sharing barriers. Efforts to develop harmonized policies and interoperability between biobanks may address some of the issues that arise in this regard.[^96^](#fn96){ref-type="fn"}

Because biobanks are costly to develop and maintain, biobank developers are looking to private investment to facilitate the long-term sustainability of these important research tools. In addition, increased pressures to commercialize---now ubiquitous in the policies of public funding agencies and universities---have encouraged biobanks to partner with private entities. While these kinds of partnerships are often necessary and can facilitate the translation of useful technologies and practices, the commercialization of biobanks also raises a host of issues that should be considered in both the development of these partnerships and relevant policy, including:

The potential to adversely impact the public trust;Consent challenges, such as the possible requirement to obtain re-consent;Exacerbating privacy issues and with the possible requirement for additional oversight or mechanisms to protect participants' privacy;Challenges for oversight bodies, such as research ethics boards, in monitoring research;Possible tensions regarding the ownership and sharing of biological samples and data; andUncertainty concerning the use and control of the resource if biobanks go bankrupt or lose funding support.
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